


Figure S1: Expression analysis of XPO1 mRNA in normal brain and three representative GBM patients and in GBM cells U87, U251 and GSC 74 after treatment with Eltanexor. * $p < 0.05$, ** $p < 0.01$, and **** $p < 0.0001$.



	Astrocyte		NSC	
	3d	5d	3d	5d
IC ₅₀ [nM]	447.7	382.8	51.91	57.78

Figure S2. Cell viability curves for Eltanexor tested in primary astrocytes and in neuronal precursor cells (NPC) after 3 and 5 days, respectively. IC₅₀ values for Eltanexor were determined and listed in the table below. All data are from three independent experiments performed in triplicates.




Figure S3: FACS analysis using propidium iodide to determine cell cycle status in U87 (E) and U251 (F) cells after treatment with Eltanexor (100 nM). Relative parts of cell cycle phases are presented in the histogram (A–D).




Figure S4: Effect of serum starvation of p53 protein levels in U87 and U251 cells in control and Eltanexor treated cells.




Figure S5: Migration of U87 (**A**) and U251 (**B**) cells after treatment with Eltanexor. Relative cell numbers were determined after 6 h for U87 and after 24 h for U251 cells. * $p < 0.05$, ** $p < 0.01$.